Tracy Walker from Managed Healthcare Executive talks with Precision for Value’s Jeremy Schafer regarding Kymriah, the first gene therapy approved for cancer treatment. Schafer flags the challenges facing payers in support of this new generation of therapies. He cites the unique outcomes-based arrangement between Novartis and CMS as one example of how manufacturers are navigating the complex landscape.

To read the complete article, please click here.